Browsing Tag
Merck & Co.
37 posts
Neuphoria Therapeutics shares jumped while Scancell plunged, and the merger terms explain why
Scancell’s Neuphoria Therapeutics merger unlocks Nasdaq access and up to $89 million, but dilution and debt reshape the iSCIB1+ outlook.
IKT-001 gains orphan status, but Inhibikase Therapeutics still faces imatinib’s safety challenge
Inhibikase Therapeutics gains FDA orphan status for IKT-001 after a $50 million raise. See how trial costs and dilution shape the outlook.
Bionyra raises $165m to build an immunology company from licensed assets
Bionyra launches with $165 million and three licensed immunology drugs. Read how its portfolio-first model could reshape biotech company creation.
Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding
Scancell is discussing an all-share acquisition of Neuphoria Therapeutics that could secure a Nasdaq listing and strengthen funding options for the global Phase 3 trial of iSCIB1+.
Merck (MRK) signs $510m AI drug discovery deal with Protillion Biosciences
Merck (MRK) signs a $510 million AI drug discovery deal with Protillion Biosciences, expanding its AI push ahead of the Keytruda patent cliff. Full analysis.
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price
Merck cleared a deal hurdle. TERN-701 now has to show whether one CML asset can justify a $6.7bn oncology bet.
Does CADENCE confirm a scalable pathway for treating complex pulmonary vascular disease beyond pulmonary arterial hypertension?
WINREVAIR’s Phase 2 data signals expansion beyond pulmonary arterial hypertension. Find out what this means for Merck & Co., Inc. and the market.